RACTS: A prospective randomized antiplatelet trial of cilostazol versus ticlopidine in patients undergoing coronary stenting: Long-term clinical and angiographic outcome

Journal of Cardiovascular Pharmacology

Volumn 46, Issue 2, 2005, Pages 162-166

  Ge, Junbo ^a   Han, Yaling ^b   Jiang, Hong ^c   Sun, Baogui ^d   Chen, Jiyan ^e   Zhang, Shuyang ^f   Du, Zhimin ^g  

^a FUDAN UNIVERSITY   (China)

^b Northern Hospital   (China)

^c WUHAN UNIVERSITY   (China)

^d SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

^e Guangdong Provincial Peoples Hospital   (China)

^f Union Hospital   (China)

^g SUN YAT SEN UNIVERSITY   (China)

Author keywords

Cilostazol; Platelet aggregation inhibitors; Restenosis; Side effect; Ticlopidine

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CILOSTAZOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; TICLOPIDINE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLEEDING; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; DEATH; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GINGIVA BLEEDING; HEADACHE; HEART INFARCTION; HEART RATE; HEMATURIA; HUMAN; LIVER DYSFUNCTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RESTENOSIS; REVASCULARIZATION; SIDE EFFECT; STROKE; SYSTOLIC BLOOD PRESSURE;

ADOLESCENT; ADULT; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CHINA; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; STENTS; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME;

EID: 23044459406     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000167012.82930.8f     Document Type: Article

References (22)

1. Fischman D, Leon M, Baim D, et al. A randomized comparison of coronary stem placement and balloon angioplasty in the treatment of coronary disease. N Engl J Med. 1994;331:496-501.
2. Serruys P, De Jaegere P, Kiemeneji F, et al. A comparison of balloon expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med. 1994;331:489-495.
3. Leon M, Bain LD, Popma J, et al. A clinical trial comparing three antithrombotic-drug regiments after coronary artery stenting. N Engl J Med. 1998;339:1665-1671.
4. Urban P, Macaya C, Rupprecht H, et al. Randomized evaluation of anticoagulation versus anti-platelet therapy after coronary stent implantation in high-risk patients: the Multicenter Aspirin and Ticlopidine Trial after Intracoronary Stenting (MATTIS). Circulation. 1998;98:2126-2132.
5. Kimura Y, Tani T, Kanbe T, et al. Effect of cilostazol on platelet aggregation and experimental thrombosis. Drug Res. 1985;35:1144-1149.
6. Kubota Y, Kichikawa K, Uchida H, et al. Pharmacologic treatment of intimal hyperplasia after metallic stent placement in the peripheral arteries. Invest Radiol. 1995;30:532-537.
7. Tsuchikane E, Fukuhara A, Kobayashi T, et al. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty. Circulation. 1999;100:21-26.
8. Sekiya M, Funada J, Watanabe K, et al. Effects of probucol and cilostazol alone and in combination on frequency of poststenting restenosis. Am J Cardiol. 1998;82:144-147.
9. Tanabe Y, Ito E, Nakagawa I, et al. Effect of cilostazol on restenosis after coronary angioplasty and stenting in comparison to conventional coronary artery stenting with ticlopidine. Int J Cardiol. 2001;78:285-291.
10. Kozuma K, Kara K, Yamasaki M, et al. Effects of cilostazol on late lumen loss and repeat revascularization after Palmaz-Schatz coronary stent implantation. Am Heart J. 2001;141:124-130.
11. Mueller C, Roskamm H, Neumann FJ, et al. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary artery stents. J Am Coll Cardiol. 2003;41:969-973.
12. Park SW, Lee CW, Kim HS, et al. Effects of cilostazol on angiographic restenosis after coronary stent placement. Am J Cardiol. 2000;86:499-503.
13. Kamishirado H, Inoue T, Mizoguchi K, et al. Randomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restenosis. Am Heart J. 2002;144:303-308.
14. Park SJ, Shim WH, Ho DS, et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med. 2003;348:1537-1545.
15. Yoon Y, Shim WH, Lee DH, et al. Usefulness of cilostazol versus ticlopidine in coronary artery stenting. Am J Cardiol. 1999;84:1375-1380.
16. Park SW, Lee CW, Kim HS, et al. Comparison of cilostazol versus ticlopidine therapy after stent implantation. Am J Cardiol. 1999;84:511-514.
17. Nagaoka N, Matsubara T, Okazaki K, et al. Comparison of ticlopidine and cilostazol for the prevention of restenosis after percutaneous transluminal coronary angioplasty. Jpn Heart J. 2001;42:43-54.
18. Dogne JM, Levai Xd X, Benoit P, et al. Recent advances in antiplatelet agents. Curr Med Chem. 2002;9:577-589.
19. Sun B, Le SN, Lin S, et al. New mechanism of action for cilostazol: interplay between adenosine and cilostazol in inhibiting platelet activation. J Cardiovasc Pharmacol. 2002;40:577-585.
20. Hayashi S, Morishita R, Matsushita H, et al. Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells, accompanied by induction of p53 and p21. Hypertension. 2000;35:237-243.
21. Morice M-C, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773-1780.
22. Serruys PW, Degertekin M, Tanabe K, et al. TAXUS II Study Group. Vascular responses at proximal and distal edges of paclitaxel-eluting stents: serial intravascular ultrasound analysis from the TAXUS II trial. Circulation. 2004;109:627-633.